Gold prices edge higher on raised Fed rate cut hopes
Yvonne Greenstreet, the Chief Executive Officer of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), a $31.4 billion market cap biotech company that has delivered an impressive 61.7% return over the past year, recently executed a series of stock transactions involving the company’s common stock. On February 27, 2025, Greenstreet acquired 5,921 shares through the vesting of restricted stock units, with each share valued at $0.00, bringing her total holdings to 87,447 shares.
The following day, February 28, 2025, Greenstreet sold a total of 2,900 shares in multiple transactions. The sales occurred at prices ranging from $236.51 to $244.11 per share, resulting in a total transaction value of $700,893. After these transactions, Greenstreet’s direct ownership of Alnylam Pharmaceuticals’ common stock stands at 84,547 shares. According to InvestingPro, the company has demonstrated strong revenue growth of 23% in the last twelve months, with 8 more exclusive insights available to subscribers.
These transactions were part of a mandatory sell-to-cover provision to satisfy tax withholding obligations related to the vesting of restricted stock units. Based on InvestingPro’s Fair Value analysis, the stock appears slightly overvalued at current levels, though detailed valuation metrics and a comprehensive Pro Research Report are available to subscribers.
In other recent news, Alnylam Pharmaceuticals has been the focus of multiple analyst updates. H.C. Wainwright raised its price target for Alnylam to $500 while maintaining a Buy rating, citing the potential of AMVUTTRA and nucresiran in treating transthyretin-mediated diseases. The company’s earnings report aligned with expectations, and management projected net product revenues between $2.05 billion and $2.25 billion for 2025. RBC Capital Markets reiterated an Outperform rating with a $310 target, highlighting Alnylam’s robust research and development pipeline and upcoming Prescription Drug User Fee Act (PDUFA) date.
Piper Sandler maintained an Overweight rating and a $304 price target, expressing optimism about the anticipated approval of AMVUTTRA for ATTR-CM, which could significantly boost sales. Canaccord Genuity also adjusted its price target slightly to $385, maintaining a Buy rating, and focused on the potential label expansion of Amvuttra for ATTR-CM. Alnylam’s upcoming Phase 3 trials for nucresiran and zilebesiran are key developments, with the company expecting to have over 25 clinical programs by the end of 2025. The firm’s R&D Day showcased advancements in RNAi technology, including new targets for obesity and type 2 diabetes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.